SG11202103031SA - Immunoablative therapies - Google Patents

Immunoablative therapies

Info

Publication number
SG11202103031SA
SG11202103031SA SG11202103031SA SG11202103031SA SG11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA SG 11202103031S A SG11202103031S A SG 11202103031SA
Authority
SG
Singapore
Prior art keywords
immunoablative
therapies
immunoablative therapies
Prior art date
Application number
SG11202103031SA
Inventor
Theresa Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of SG11202103031SA publication Critical patent/SG11202103031SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
SG11202103031SA 2018-10-03 2019-10-03 Immunoablative therapies SG11202103031SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18198491.5A EP3488851A1 (en) 2018-10-03 2018-10-03 Immunoablative therapies
PCT/US2019/054395 WO2020072713A1 (en) 2018-10-03 2019-10-03 Immunoablative therapies

Publications (1)

Publication Number Publication Date
SG11202103031SA true SG11202103031SA (en) 2021-04-29

Family

ID=63762311

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103031SA SG11202103031SA (en) 2018-10-03 2019-10-03 Immunoablative therapies

Country Status (14)

Country Link
US (2) US11446314B2 (en)
EP (2) EP3488851A1 (en)
JP (1) JP2020059703A (en)
KR (1) KR20210072039A (en)
CN (1) CN113164497A (en)
AU (1) AU2019355004A1 (en)
BR (1) BR112021006280A2 (en)
CA (1) CA3113969A1 (en)
EA (1) EA202190927A1 (en)
ES (1) ES2863369T3 (en)
MX (1) MX2021003797A (en)
SG (1) SG11202103031SA (en)
WO (1) WO2020072713A1 (en)
ZA (1) ZA202102727B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130253A (en) * 2018-11-14 2022-09-26 에이브이엠 바이오테크놀로지, 엘엘씨 Stable Glucocorticoid Formulation
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same
CN115666583A (en) 2020-04-29 2023-01-31 Avm生物技术有限责任公司 Glucocorticoid Receptor (GR) modulators for the treatment of SARS-COV-2 virus
WO2021247000A1 (en) * 2020-06-01 2021-12-09 Avm Biotechnology, Llc Methods of treatment using icam-modulating agents
KR20220163638A (en) 2021-06-03 2022-12-12 현대모비스 주식회사 Brake Apparatus for Vehicle and Control Method Therefor
WO2023034377A1 (en) 2021-09-01 2023-03-09 Avm Biotechnology, Llc Lymphocyte population and methods for producing same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3368937A (en) * 1965-01-26 1968-02-13 Merck & Co Inc Injectable solid steroid-anesthetic
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
WO2003077864A2 (en) 2002-03-15 2003-09-25 Department Of Veterans Affairs, Rehabilitation R & D Service Methods and compositions for directing cells to target organs
MXPA04010927A (en) * 2002-05-02 2006-01-30 Univ Washington Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency.
CN100436763C (en) * 2002-05-08 2008-11-26 Btu国际公司 Plasma-assisted engine exhausting process
EP2105136A3 (en) 2002-05-17 2010-01-27 Celgene Corporation Pharmaceutical compositions for treating cancer
JP3968334B2 (en) 2002-09-11 2007-08-29 株式会社日立ハイテクノロジーズ Charged particle beam apparatus and charged particle beam irradiation method
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
CA2592435C (en) 2004-12-23 2017-03-28 Ethicon, Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
RU2468797C2 (en) * 2005-06-09 2012-12-10 Биолипокс Аб Method and composition for treatment of inflammatory disorders
BRPI0613770A2 (en) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anti-cd26 antibodies and methods of use of these
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
ES2627043T3 (en) 2008-06-09 2017-07-26 Targazyme, Inc. Increased effectiveness of cell therapy including treatment with alpha 1-3 fucoslitransferase
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
RU2645069C2 (en) 2010-08-18 2018-02-15 Авм Байотекнолоджи, Ллс Compositions and methods for inhibition of stem cells and precursor cells binding with lymphoid tissue and for regeneration of germinal centers in lymph tissues
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
PL3214091T3 (en) 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EA201391059A1 (en) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания COMPOSITIONS FOR CANCER TREATMENT AND METHODS OF THEIR APPLICATION
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2756521A4 (en) 2011-09-16 2015-04-22 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
US20130287747A1 (en) 2012-04-30 2013-10-31 Allocure, Inc. Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
KR20230147769A (en) 2015-05-28 2023-10-23 카이트 파마 인코포레이티드 Methods of conditioning patients for t cell therapy
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
SG11201907744QA (en) 2017-04-01 2019-09-27 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy

Also Published As

Publication number Publication date
JP2020059703A (en) 2020-04-16
US20210338689A1 (en) 2021-11-04
EP3488851A1 (en) 2019-05-29
ZA202102727B (en) 2022-05-25
WO2020072713A1 (en) 2020-04-09
US20200108078A1 (en) 2020-04-09
KR20210072039A (en) 2021-06-16
BR112021006280A2 (en) 2021-07-06
US11446314B2 (en) 2022-09-20
EP3860612A1 (en) 2021-08-11
MX2021003797A (en) 2021-08-11
CN113164497A (en) 2021-07-23
CA3113969A1 (en) 2020-04-09
AU2019355004A1 (en) 2021-05-06
ES2863369T3 (en) 2021-10-11
EA202190927A1 (en) 2021-08-02

Similar Documents

Publication Publication Date Title
ZA202102016B (en) Combination therapies
IL274407A (en) Combination therapies
IL271011A (en) Triple combination antibody therapies
IL263680A (en) Combination therapies
PT3810587T (en) Substituted alkoxypyridinyl indolsulfonamides
ZA202102727B (en) Immunoablative therapies
GB201800761D0 (en) Interaction between blockchains
EP3423094A4 (en) Gfral receptor therapies
ZA202102015B (en) Combination therapies
IL291659A (en) Combination therapies
HK1243598A1 (en) Combination therapies
IL281526A (en) Rail-switching unit
GB201901651D0 (en) The geness project
GB201901639D0 (en) The blockworld project
IL276999A (en) Breastshield unit
GB201703907D0 (en) Novel therapies for cancer
GB201916906D0 (en) Combination therapies
GB2612702B (en) Host-biome interactions
GB201902311D0 (en) The nautica project
GB201807046D0 (en) Combination
IL287667A (en) Combination therapies
GB201908621D0 (en) Construction set
GB201902722D0 (en) The Krishi project
GB201819369D0 (en) Maglee plane
GB201807559D0 (en) Saddle